Cancer kills eight million people annually worldwide; this number will increase to 13 million by 2020. Lung, breast, colorectal, and prostate cancer are the four most commonly diagnosed cancers. Meaningful developments in immuno-oncology, or cancer immunotherapy, treatments are important now more than ever. Learn about some of the newer immunotherapies, including BiTE Antibodies and vaccines, and the companies developing them.
Immunotherapy is not a new concept; it has, in fact, been around for more than 125 years. However, recent scientific advances have led to the emergence and rapid evolution of the field, especially immuno-oncology. Get an introduction to this exciting emerging field, learn about the different personalized therapies currently available, and see what the future of cancer immunotherapy looks like.
The power to edit a gene is the power to change its function, and with it the biology of a cell. From generating novel cell lines and better animal models for the discovery and preclinical phases of therapeutic research to actually creating a therapeutic itself, CRISPR gene editing is allowing science to advance rapidly. See how enrichment and cell sorting can help generate edited cells faster and more reliably.
In this podcast, biosimilar expert, Amanda Turner, provides an in-depth explanation of the various in vitro assays used in biosimilar development and the importance of choosing the right assay type and components to achieve success.
Biomarker intelligence comes from understanding the biomarker landscape, that is, the characteristics and features of biomarkers, and disease pathways. This understanding, in turn, helps to recognize the utility of biomarkers. In this study, we partnered with Amplion Inc., to investigate biomarker usage in 24 immunotherapy companies. We found the most popular biomarkers and learnt how they are being used by each company.
Is the hype surrounding biosimilars real or simply a hopeful view on an exceedingly expensive drug market? Read this article to find out more about biosimilars and understand the challenges facing the biosimilars industry.
In this podcast, learn more about biomarkers and their importance in clinical trials and how data-rich tools are being used to collect and curate the vast amounts of publicly available information about biomarkers.
Our resident gene editing expert, Dr. Yann Jouvenot, provides an overview of CRISPR gene editing and how it is affecting how research and development are being performed in the Biotech and Pharma industries.
The typical success rate of a clinical trial is less than ten percent. Pharmaceutical companies are using a variety of methods to save time and reduce costs to get drugs to market faster. Biomarker screening is proving to be an effective way to improve the drug discovery and development process. See one of the ways Pharma companies can identify the most relevant biomarkers.
Our resident gene editing expert, Dr. Yann Jounenvat, provides an overview of the four main gene editing techniques that are being used in life science research today. Learn about the pros and cons of each of method and where they are best applied.